ID: h-5d374a18a2
Hypothesis
Propionate may outperform acetate or butyrate at physiological exposure, but mainly as a weak resilience signal rather than a true alpha-synuclein clearance therapy
Propionate is the most plausible exploratory monotherapy candidate only because it may have somewhat more realistic systemic signaling potential than butyrate, but the evidence base is thin and not specific to aggregate clearance.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 8 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Propionate is the most plausible exploratory monotherapy candidate only because it may have somewhat more realistic systemic signaling potential than butyrate, but the evidence base is thin and not specific to aggregate clearance. It should remain a comparator arm in PK/PD studies, not a primary translational program.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Gut Dysbiosis<br/>Reduced Short-Chain Fatty Acids"]
B["Propionate Deficiency<br/>Systemic and CNS"]
C["FFAR3 Free Fatty Acid<br/>Receptor 3 Signal Loss"]
D["STAT3 Anti-Inflammatory<br/>Signaling Reduction"]
E["Microglial Pro-Inflammatory<br/>Activation"]
F["Neuroinflammation<br/>AD/PD Pathology"]
G["Propionate Supplementation<br/>FFAR3 Rescue"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.-> C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style C fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix8 supports2 contradicts
Supports
Propionic acid improved survival-related signals in rotenone-lesioned primary mesencephalic dopaminergic neurons and increased TH and STAT3-related measures in vitro.
Supports
SCFA receptor biology supports the possibility of receptor-mediated signaling at realistic concentrations.
Supports
Propionic Acid Induces Gliosis and Neuro-inflammation through Modulation of PTEN/AKT Pathway in Autism Spectrum Disorder.
Supports
Microbial production of short-chain fatty acids attenuates long-term neurologic impairment after traumatic brain injury.
Supports
Sodium butyrate attenuates microglia-mediated neuroinflammation by modulating the TLR4/MyD88/NF-κB pathway and microbiome-gut-brain axis in cardiac arrest mice.
Supports
Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells.
Supports
Microbially-derived short-chain fatty acids impact astrocyte gene expression in a sex-specific manner.
Supports
Anti-neuroinflammatory Effect of Short-Chain Fatty Acid Acetate against Alzheimer's Disease via Upregulating GPR41 and Inhibiting ERK/JNK/NF-κB.
Contradicts
The supporting evidence is in vitro, not alpha-synuclein-clearance-specific, and does not establish in vivo efficacy at physiologic exposure.
Contradicts
The broader debate evidence indicates that physiologic systemic SCFA exposure is generally too low to justify strong monotherapy claims.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — FFAR3
No curated PDB or AlphaFold mapping for FFAR3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for FFAR3/STAT3 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for FFAR3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.4%
Volatility
Low
0.0152
Events (7d)
2
Price History
▲10.7%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6J mice receiving intravenous propionate at physiological concentrations (2mM) for 8 weeks are compared against mice receiving equimolar acetate or butyrate in a preformed α-synuclein fibril | Propionate superiority over acetate and butyrate in reducing striatal α-synuclein aggregate burden by ≥40% | — no observation — | pending | 0.25 |
| IF differentiated SH-SY5Y cells with preformed α-synuclein aggregates are treated with propionate at 1mM for 72 hours, THEN cellular aggregate load will not decrease more than 15% from baseline (indic | ≤15% reduction in preformed aggregate load; observed effects attributed to anti-aggregation rather than clearance mechanisms | — no observation — | pending | 0.30 |
🔮 Falsifiable Predictions (2)
pendingconf 30%
IF differentiated SH-SY5Y cells with preformed α-synuclein aggregates are treated with propionate at 1mM for 72 hours, THEN cellular aggregate load will not decrease more than 15% from baseline (indicating weak resilience signaling), and any reduction will be attributable to decreased aggregation se
Predicted outcome: ≤15% reduction in preformed aggregate load; observed effects attributed to anti-aggregation rather than clearance mechanisms
Falsification: Reduction of >15% in preformed aggregates would indicate genuine clearance activity, disproving the 'weak resilience signal' characterization
pendingconf 25%
IF C57BL/6J mice receiving intravenous propionate at physiological concentrations (2mM) for 8 weeks are compared against mice receiving equimolar acetate or butyrate in a preformed α-synuclein fibril seeding model, THEN propionate-treated mice will show at least 40% greater reduction in striatal α-s
Predicted outcome: Propionate superiority over acetate and butyrate in reducing striatal α-synuclein aggregate burden by ≥40%
Falsification: No statistically significant superiority of propionate over acetate or butyrate (p>0.05), or equivalent/better efficacy in comparator arms would disprove the specificity claim
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.